Henan Lingrui Pharmaceutical600285.SHValuation Analysis
Based on the blended 10-year P/E and P/B percentiles, the stock currently sits in the “Fair Value Range” zone.
As of Oct 19, 2026, Henan Lingrui Pharmaceutical (600285.SH) trades at a P/E of 15.30x, P/B of 3.70x, P/S of 2.78x, and a dividend yield of 5.22%.
Longitudinal percentile comparison: P/E sits at the 10th percentile over the trailing 10Y window (vs. 18th percentile over 3Y); P/B sits at the 79th percentile over the trailing 10Y window (vs. 40th percentile over 3Y); P/S sits at the 55th percentile over the trailing 10Y window (vs. 23rd percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 10th percentile within its industry and the 14th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 5.22%, ranking at the 90th percentile over the trailing 20Y window.
The P/E and P/B percentiles diverge here, differing by 69.4 points — relying on either metric alone could be misleading. Its P/E percentile is roughly the same whether measured against the industry or the broader market. Shareholder returns here are driven almost entirely by cash dividends, with minimal contribution from buybacks. Henan Lingrui Pharmaceutical operates in the Medicine sector. Data refreshes weekly and is for reference only, not investment advice.
Also listed as: SHA: 600285 · SSE: 600285 · 600285
Want the full picture on whether Henan Lingrui Pharmaceutical (600285.SH) is under- or over-valued? See the full 3Y / 5Y / 10Y / 20Y P/E, P/B, P/S, Dividend Yield & Total Shareholder Yield percentile matrix and the interactive ECharts trend chart on this page.
Historical Percentiles by Metric
| Metric | Current | Market Percentile | Industry Percentile | 3Y Pctl | 5Y Pctl | 10Y Pctl | 20Y Pctl |
|---|---|---|---|---|---|---|---|
| P/E (TTM) | 15.30 | ||||||
| P/B (MRQ) | 3.70 | ||||||
| P/S (TTM) | 2.78 | ||||||
| Dividend Yield | 5.22% | ||||||
| Buyback + Div Yield | 5.22% |